NCT07668167 Combined Regulatory Effects of 40 Hz eTNS and Multisensory Stimulation on Brain Networks
| NCT ID | NCT07668167 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xidian University |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-16 |
| Primary Completion | 2026-06-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-06-16 with a primary completion date of 2026-06-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to investigate the independent and interactive effects of 40Hz auditory, visual, and external trigeminal nerve stimulation (eTNS) on brain state dynamics and functional connectivity. While 40Hz visual and auditory sensory stimulation have been explored for potential cognitive and therapeutic benefits, the underlying mechanisms on large-scale brain networks and the potential effects of combining multiple modalities remain unclear. This study aims to determine whether multimodal co-stimulation genuinely compounds network-level effects or if targeted dual-pairings are more efficient for brain network reorganization. In this within-subject study, 23 participants will receive all eight possible combinations of 40Hz auditory, visual, and eTNS (targeting the maxillary branch) in a randomized order. Each stimulation condition will last for 5 minutes, separated by 1-minute inter-stimulus intervals. Continuous electroencephalography (EEG) will be recorded throughout the procedures to evaluate brain responses. The collected EEG data will be analyzed using microstate analysis, functional connectivity analysis, and graph-theoretic network analysis. Ultimately, the study seeks to understand how these non-invasive stimulation techniques, independently and together, drive large-scale network reorganization and optimize the balance between local specialization and global integration in the brain.
Eligibility Criteria
Inclusion Criteria: * Healthy adults aged ≥18 years old. * Normal or corrected-to-normal vision and hearing (essential for 40Hz visual and auditory stimulation). * Right-handedness. * Willing to participate in the study and capable of providing written informed consent. Exclusion Criteria: * Personal or family history of epilepsy or seizures (crucial safety criteria for 40Hz flicker and electrical stimulation). * History of any neurological or psychiatric disorders. * Presence of metallic implants in the head, cardiac pacemakers, or other implanted electronic medical devices. * Skin lesions, infections, or hypersensitivity at the eTNS stimulation site (maxillary branch of the trigeminal nerve). * Current use of psychoactive medications or substances that may significantly alter EEG signals or brain state dynamics. * Pregnant or lactating individuals. * Poor sleep quality or irregular sleep-wake cycles prior to the experiment.
Contact & Investigator
Xue-Juan Yang
PRINCIPAL INVESTIGATOR
Xidian University
Frequently Asked Questions
Who can join the NCT07668167 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07668167 currently recruiting?
Yes, NCT07668167 is actively recruiting participants. Contact the research team at xjyang@xidian.edu.cn for enrollment information.
Where is the NCT07668167 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT07668167 clinical trial?
NCT07668167 is sponsored by Xidian University. The principal investigator is Xue-Juan Yang at Xidian University. The trial plans to enroll 30 participants.